Cytek Biosciences
CTKB
84 hedge funds and large institutions have $568M invested in Cytek Biosciences in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 14 closing their positions.
112% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 17
86% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 14
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
14% more funds holding
Funds holding: 74 → 84 (+10)
10% more capital invested
Capital invested by funds: $515M → $568M (+$53.3M)
3.78% more ownership
Funds ownership: 35.59% → 39.37% (+3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
+$20.9M |
| 2 |
BlackRock
New York
|
+$10.4M |
| 3 |
RI
RTW Investments
New York
|
+$9.13M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.01M |
| 5 |
Millennium Management
New York
|
+$7.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MGM
Miura Global Management
New York
|
-$6.03M |
| 2 |
Goldman Sachs
New York
|
-$5.72M |
| 3 |
Two Sigma Investments
New York
|
-$5.65M |
| 4 |
D.E. Shaw & Co
New York
|
-$5.21M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.17M |
CTKB Hedge Fund Activity: Q2 2022 in Review
84 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q2 2022, worth a combined $568M — up 10% from $515M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CTKB positions and 14 closed out — a net gain of 12 holders — while 36 added to existing stakes and 17 trimmed.
The largest buyer was Blue Water Life Science Advisors, opening a new position worth an estimated $20.9M. The largest seller was Miura Global Management, cutting an estimated $6.03M.
- 84 institutional investors held Cytek Biosciences (CTKB) as of Q2 2022, up from 74 in Q1 2022.
- Funds reported $568M of Cytek Biosciences stock for Q2 2022, up 10% quarter-over-quarter.
- 26 funds opened new Cytek Biosciences positions in Q2 2022 and 14 closed out, a net change of +12 holders.
- The largest Cytek Biosciences buyer in Q2 2022 was Blue Water Life Science Advisors, an estimated $20.9M added.
- The largest Cytek Biosciences seller in Q2 2022 was Miura Global Management, an estimated $6.03M sold.
Based on aggregated 13F filings for Q2 2022.